AstraZeneca Reports Q3 Revenue Up 18% Amid Strong Oncology Demand, Raises Full-Year Guidance

Gelonghui November 12 | British pharmaceutical company AstraZeneca announced its third-quarter results, with revenue of $13.575 billion, a year-on-year increase of 18%, surpassing the analyst expectation of $13.1 billion; core earnings per share were $2.08, up 20% year-on-year, higher than the analyst forecast of $2.04. Product sales during the period reached $12.95 billion, an increase of 18% year-on-year, mainly driven by strong demand for its top-selling cancer drugs Imfinzi, Tagrisso, and Calquence.

In the first nine months of this year, total revenue reached US$39.182 billion, a year-on-year increase of 16%; of which product sales amounted to US$37.576 billion, a year-on-year increase of 16%. Core earnings per share were US$6.12, a year-on-year increase of 5%; operating profit margin was 32%.

The company raised its full-year guidance, expecting both full-year revenue and core earnings per share to achieve a high double-digit percentage increase, up from the previous forecast of mid-double digits. Additionally, the company announced a $3.5 billion investment in research and development in the United States. (Gelonghui)